

Date	Last Name	First Name	Affiliation	Title
15.01.2025	Ferrucci	Pier Francesco	Multimedica Milano, IT	New checkpoints combinations in the neoadjuvant setting
19.02.2025	Hierro	Cinta	Catalan Institute of Oncology, ES	New targets for the development of new antibodies
26.03.2025	Simonelli	Matteo	IRCCS Humanitas Research Hospital, IT	Bispecific antibodies in solid tumors
16.04.2025	Steeghs	Neeltje	Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital , NL	Pharmacokinetics of Antibody-drug conjugates: are they important?
14.05.2025	Pentheroudakis	George	European Society of Medical Oncology, CH	The ESMO portfolio of Frameworks for optimising research and practice in Oncology: Tumour Agnostic Classifier/Screeners and others
25.06.2025	Postel-Vinay	Sophie	Institut Gustave Roussy, FR	Protein degraders: state of the art and future use
24.09.2025	Thistlethwaite	Fiona	Christie NHS Foundation Trust, UK	Updates on CAR-T cells in solid tumors
29.10.2025	Petak	Istvan	Genomate Health, US	Computer-assisted molecularly targeted therapy in oncology
19.11.2025	Pignatti	Francesco	European Medicines Agency, NL	Biomarkers use in clinical trials: the regulatory perspective